Abstracts tagged "Arthritis and polymyalgia rheumatica"

Abstract Number: 354 • 2018 ACR/ARHP Annual Meeting
Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
Mazen Nasrallah¹, Meghan Mooradian², Eli Miloslavsky³, Justine Cohen², Justin Gainor², Donald Lawrence², Kerry Reynolds², Minna Kohler⁴, Ryan Sullivan² and Sara Schoenfeld¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have led to improved outcomes in multiple cancers, but they are associated with immune-related adverse events (irAEs), including inflammatory arthritis.…
Abstract Number: 1184 • 2017 ACR/ARHP Annual Meeting
Response to Methotrexate and Glucocorticoid Injection in New Onset Arthritis after Checkpoint Inhibitor Therapy
Lisa Christ¹, Jan Leipe¹, Ilana Goldscheider², Markus Heppt², Carola Berking², Frank Berger³, Claudia Dechant¹, Alla Skapenko¹ and Hendrik Schulze-Koops¹, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ²Department of Dermatology and Allergology, University of Munich, Munich, Germany, ³Department of Radiology, University of Munich, Munich, Germany
Background/Purpose: The recent introduction of biologic agents targeting immunologic checkpoints (immunologic checkpoint inhibitors, ICI) established immunotherapy as a highly effective cancer therapy. ICI that trigger…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].